【摘要】 目的:观察吉西他滨单药治疗老年晚期非小细胞肺癌的疗效、临床受益反应(CBR)及毒副反应。方法:34例Ⅲb~Ⅳ期老年非小细胞肺癌患者采用吉西他滨1 000 mg/m2,第1、8、15 d静滴,每28 d为1周期。按WHO标准评估疗效及毒副反应,同时评估CBR指标。结果:PR 9例,SD 20例,PD 3例,有效率28.1%,CBR为65.6%。毒副反应轻,老年患者也能耐受。结论:采用吉西他滨单药治疗老年晚期非小细胞肺癌疗效好、低毒、安全,可作为老年晚期非小细胞肺癌患者的一线治疗方案。更多还原

【Abstract】 Objective:To investigate the efficacy,clinical-benefit-response(CBR),toxic and side-effect of gemcitabine monotherapy in treating advanced non-small-cell lung cancer in elderly patients.Methods:34 elderly patients with the carcinoma(stage ⅢB-Ⅳ)were treated with single agent gemcitabine 1 000 mg/m2 on the 1st,8th and 15th day,respectively,in a treatment cycle of 28 days by intravenous drip.The clinical efficacy and toxicity were estimated according to criteria of WHO reference and the CBR was evaluated as well.Results:The partial response was found in 9 patients,stable disease in 12 and progressive disease in 3.The effective rate was 28.1%,and the less side-effects resulted in a relative tolerance for the elderly patients.Conclusion:Gemcitabine monotherapy in the treatment of elderly advanced non-small-cell lung cancer is highly effective and safe with low toxic and side-effects,therefore,it can be recommended to the clinical use for advanced non-small-cell lung cancer in elderly patients.更多还原